PolynovoASX:PNV -3.70%76 FCF Margin % is -2.48% as of Dec. 2025. GuruFocus rates ASX:PNV with a GF Score™ of 76/100 and a GF Value™ of A$3.24 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Polynovo ranks better than 59.63% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Polynovo's Free Cash Flow for the
six
months ended in Dec. 2025 was A$-1.7 Mil. Polynovo's Revenue for the
six
months ended in Dec. 2025 was A$70.2 Mil. Therefore, Polynovo's FCF Margin % for the quarter that ended in Dec. 2025 was -2.48%.
The historical rank and industry rank for Polynovo's FCF Margin % or its related term are showing as below:
ASX:PNV'
s FCF Margin % Range Over the Past 10 Years
Min: -158.76 Med: -27.53 Max: 3.73
Current: 3.73
During the past 13 years, the highest FCF Margin % of Polynovo was 3.73%. The lowest was -158.76%. And the median was -27.53%.
ASX:PNV's FCF Margin % is ranked better than 59.63% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.03
vs ASX:PNV: 3.73
Polynovo FCF Margin % Related Terms
Polynovo FCF Margin % Historical Data
* Premium members only.
The historical data trend for Polynovo's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Polynovo's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Polynovo FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Polynovo's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Polynovo's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Polynovo (ASX:PNV) has a FCF Margin % of -2.48% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Polynovo and its competitors. According to the industry distribution chart, Polynovo ranks #329 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 40.4%.
Is Polynovo's FCF Margin % too high?
Polynovo's current FCF Margin % is -2.48%. Based on the distribution chart, Polynovo ranks #329 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Polynovo has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Polynovo's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Polynovo ranks #329 out of 815 companies for FCF Margin %. This puts Polynovo in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Polynovo and its competitors. Polynovo's current FCF Margin % is -2.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polynovo stock overvalued right now?
Based on GuruFocus' analysis, Polynovo (ASX:PNV) is currently considered Significantly Undervalued. The stock's GF Value™ is A$3.24, compared to a current price of A$0.91 — trading 71.9% below its estimated fair value. The current FCF Margin % is -2.48%. Polynovo's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Polynovo (ASX:PNV), the current FCF Margin % is -2.48% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Polynovo (ASX:PNV) Overvalued in 2026?
Based on GuruFocus' analysis, Polynovo stock appears to be undervalued.
The current stock price of A$0.91 is trading 71.9% below its estimated GF Value™ of A$3.24.
GuruFocus considers Polynovo to be Significantly Undervalued.
Key valuation signals for ASX:PNV:
FCF Margin %: -2.48%
GF Value™: A$3.24 vs. price of A$0.91 (71.9% below fair value)
No single metric tells the full story. See the ASX:PNV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
76GF Score
Get the complete analysis for ASX:PNV
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PNV has been successfully added to your 
